| CAS NO: | 2375193-43-2 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 2375193-43-2 |
| Canonical SMILES | FC(C=C1)=CC=C1COC2=C(OCC3=CC=C(F)C=C3)C=C(CNCCO)C=C2.Cl |
| 分子式 | C23H24ClF2NO3 |
| 分子量 | 435.89 |
| 溶解度 | DMSO : 150 mg/mL (344.12 mM);Water : 0.91 mg/mL (2.09 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | XRK3F2 is an inhibitor of p62 (Sequestosome-1)-ZZ/ domain. The presence of XRK3F2 during MM-preOB co-cultures prevents Runx2 suppression at both d0 and d4. Furthermore, XRK3F2 blocks MM-induced upregulation of Gfi1. XRK3F2 blocks the induction of Gfi1 mRNA in BMSC in both treatment conditions. In contrast, XRK3F2 prevents both MM1.S CM and TNFα plus IL7-mediated Runx2 suppression. Further, the pro-inflammatory and myeloma pro-survival factor IL6 mRNA is also reduced by XRK3F2 treatment. In addition, XRK3F2 also prevents TNFα-mediated upregulation of Gfi1 and rescues inhibition of Runx2 in MC4 preOB. XRK3F2 prevents MM-induced GFI1 occupancy at the Runx2-P1 promoter. XRK3F2 treatment significantly rescues the H3K9ac levels at Runx2 in MM patient hBMSC and XRK3F2 can rescue early steps in osteogenesis[1]. [1]. Adamik J, et al. XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression. Front Endocrinol (Lausanne). 2018 Jun 29;9:344. |
m.cnreagent.com